Compare QUALCOMM, Inc. (QCOM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Qualcomm (QCOM) trades at $177.06, down 2.21% today, with a bearish technical signal and support near $175. The company reported strong revenue of $44.28B in 2025 but net income fell to $5.54B, reflecting margin pressure. Recent news highlights a strategic AI partnership with Amazon, potentially opening a $60B opportunity, while analyst consensus remains mixed with a $204.48 price target.

QCOM's outlook is balanced by AI growth potential against near-term headwinds. The Amazon deal and diversification into automotive and data centers offer upside, but execution risks, competition, and dependence on smartphone markets pose challenges. Valuation metrics like a P/E of 20.12 appear reasonable if AI initiatives accelerate revenue.

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.